Amadeo B. Biter

Sep 11, 2024 | digitalcommons.library.tmc.edu | Ji Hee Son |Heather Lin |Siqing Fu |Amadeo B. Biter

INTRODUCTION: We aimed to identify clinical, pathologic, and treatment factors that are predictive of response and survival in patients with cervical cancer referred to phase I clinical trials. METHODS: Patients with cervical cancer who received at least one dose of a phase I investigational agent at our institution between 2014 and 2022 were included.